Skip to content

Postmarketing Surveillance Study with VISIPAQUE 270/320

VISIPAQUE(Iodixanol) 270/320

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-11003061
Enrollment
Unknown
Registered
2011-07-15
Start date
2011-07-11
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CCTA/CECT, IR, CAG+/-PCI

Interventions

none:none

Sponsors

Fu wai Cardiovascular Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients who were referred to the study sites for CECT/CCTA, IR, CAG and/or PCI and who had given written informed consent to have their data collected for the study were enrolled. The patients enrolled were 18 years of age or older, patients had no contraindications according to the SPC for VISIPAQUE 270/320 mgI/ml in China.

Exclusion criteria

Exclusion criteria: Patients with uncontrollable hyperthyroidism and has serious adverse reaction; History of Iodixanol.

Design outcomes

Primary

MeasureTime frame
allergic, non-allergic adverse drug reaction (such as hot/cool/pain/uncomfortable);

Countries

China

Contacts

Public ContactLu Bin
blu@vip.sina.com+86 13911285857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026